STOCK TITAN

Arcus Biosciences Announces New Employment Inducement Grants

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

Key Terms

restricted stock units financial
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
exercise price financial
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
inducement exception regulatory
An inducement exception is a narrow allowance in financial rules that lets a firm make a specific payment or offer an incentive that would otherwise be prohibited, typically to recruit a key employee or to win a client under tightly controlled conditions. For investors, it matters because such exceptions can increase a company’s costs, create potential conflicts of interest, and signal regulatory scrutiny or special circumstances—like a recruiter offering a signing bonus that a standard policy would normally ban—so they affect both expense forecasts and governance risk.
nyse listed company manual rule 303a.08 regulatory
NYSE Listed Company Manual Rule 303A.08 is a rule that requires companies listed on the New York Stock Exchange to have a plan for how they will handle a sudden loss of significant business or assets. It helps ensure companies are prepared for major setbacks, protecting investors by encouraging strong risk management practices.
inducement plan financial
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 17,050 shares of the Company’s common stock at an exercise price per share of $23.43, which was the closing price on March 9, 2026, and restricted stock units to acquire a total of 8,550 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for the treatment of cancer and inflammatory and autoimmune diseases. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of its late-stage portfolio of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.

Inducement PR

Source: Arcus Biosciences

Investor & Media Inquiries

Holli Kolkey

VP of Corporate Affairs

(650) 922-1269

hkolkey@arcusbio.com

Maryam Bassiri

Director, Corporate Affairs

(510) 406-8520

mbassiri@arcusbio.com

Source: Arcus Biosciences

Arcus Bioscience

NYSE:RCUS

View RCUS Stock Overview

RCUS Rankings

RCUS Latest News

RCUS Latest SEC Filings

RCUS Stock Data

2.77B
85.51M
Biotechnology
Pharmaceutical Preparations
Link
United States
HAYWARD